


This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims:

1. (Currently Amended) A compound according to the general Formula (I)



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, or ~~and~~ the N-oxide form thereof, wherein:

- X is CH₂, N-R⁷, S or O;
- R⁷ is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, alkylcarbonyl, alkyloxycarbonyl and mono- and dialkylaminocarbonyl;
- B is a radical, optionally substituted with r radicals R', according to anyone of Formula (B-a) or (B-b) and fused to the isoxazolinyl moiety by either of the bond pairs (c,d), (d,e) or (e,f)



wherein

- Het is an optionally substituted 5- or 6-membered heterocyclic ring, selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, oxadiazolyl and triazolyl ;


each R^1 is, independently from each other, selected from the group consisting of hydrogen, hydroxy, amino, nitro, cyano, halo and alkyl and, only when R^1 is attached to a N-atom, is further selected from the group of alkyloxyalkyl, alkyloxyalkyloxyalkyl, alkyloxycarbonylalkyl, formyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl and mono- and dialkylaminocarbonyl;

r is an integer ranging from 0 to 6 ;

a and b are asymmetric centers ;

$(CH_2)_m$ is a straight hydrocarbon chain of m carbon atoms, m being an integer ranging from 1 to 4 ;

Pir is a radical according to any one of Formula (IIa), (IIb) or (IIc)



optionally substituted with n radicals R^8 , wherein :

each R^8 is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo and alkyl ;

n is an integer ranging from 0 to 5 ;

R^9 is selected from the group consisting of hydrogen, alkyl and formyl ;


R^3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system together with an optionally substituted and partially or completely hydrogenated hydrocarbon chain of 1 to 6 atoms long with which said ring system is attached to the Pir radical and of which may contain one or more heteroatoms selected from the group of O , N and S;

Ar is phenyl or naphthyl, optionally substituted with one or more halo, cyano, oxo, hydroxy, alkyl, formyl, alkyloxy or amino radicals ; and

alkyl represents a straight or branched saturated hydrocarbon radical having from 1

to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals.

2. (Currently Amended) The [[A]] compound according to claim 1, wherein ~~characterized in that~~ R^3 is a radical according to any one of Formula (IIIa), (IIIb) or (IIIc)



wherein :

- d is a single bond while Z is a bivalent radical selected from the group consisting of $-\text{CH}_2-$, $-\text{C}(=\text{O})-$, $-\text{CH}(\text{OH})-$, $-\text{C}(=\text{N}-\text{OH})-$, $-\text{CH}(\text{alkyl})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$, $-\text{NH}-$ and $-\text{SH}-$; or d is a double bond while Z is a trivalent radical of formula $=\text{CH}-$ or $=\text{C}(\text{alkyl})-$;
- A is a 5- or 6-membered aromatic homocyclic or heterocyclic ring, selected from the group consisting of phenyl, pyranyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, oxadiazolyl and isoxazolyl ;
- P is an integer ranging from 0 to 6 ;
- R^4 and R^5 are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, biphenyl, halo and cyano ; or
- R^4 and R^5 may be taken together to form a bivalent radical $-\text{R}^4-\text{R}^5-$ selected from the group consisting of $-\text{CH}_2-$, $=\text{CH}-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$, $-\text{O}-$, $-\text{NH}-$,

=N-, -S-,

-CH₂N(-alkyl)-, -N(-alkyl)CH₂-, -CH₂NH-, -NHCH₂-, -CH=N-, -N=CH-,

-CH₂O- and -OCH₂- ;

each R⁶ is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo, carboxyl, alkyl, Ar, alkyloxy, Ar-oxy, alkylcarbonyloxy, alkyloxycarbonyl, alkylthio, mono- and di(alkyl)amino, alkylcarbonylamino, mono- and di(alkyl)aminocarbonyl, mono- and di(alkyl)aminocarbonyloxy, mono- and di(alkyl)aminoalkyloxy ; or

two vicinal radicals R⁶ may be taken together to form a bivalent radical

-R⁶-R⁶- selected from the group consisting of -CH₂-CH₂-O-, -O-CH₂-CH₂-,

-O-CH₂-C(=O)-, -C(=O)-CH₂-O-, -O-CH₂-O-, -CH₂-O-CH₂-, -O-CH₂-

CH₂-O-, -CH=CH-CH=CH-, -CH=CH-CH=N-, -CH=CH-N=CH-,

-CH=N-CH=CH-, -N=CH-CH=CH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-C(=O)-,

-C(=O)-CH₂-CH₂-, -CH₂-C(=O)-CH₂- and -CH₂-CH₂-CH₂-CH₂ and

R¹⁶ is selected from the group consisting of hydrogen, alkyl, Ar and Ar-alkyl.

3. (Currently Amended) The [[A]] compound according to claim 2, wherein X = O ; m = 1 ; B is a radical according to Formula (B-a) or (B-b), Pir is a radical according to Formula (IIa) wherein n = 0 ; R³ is a radical according to according to any one of Formula (IIIa), (IIIb) or (IIIc) wherein d is a double bond while Z is a trivalent radical of formula =CH- or =C(alkyl)-; A is a phenyl ring; R⁴ is hydrogen or alkyl ; R⁵ and R¹⁶ are each hydrogen ; R⁶ is hydrogen or halo and p = 1.

4. (Previously Presented) A compound according to claim 1 wherein Het is selected from the group consisting of pyridinyl, thienyl and pyrrolyl, each radical optionally substituted on a N atom with a radical selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, alkyloxyalkyloxyalkyl, alkyloxycarbonylalkyl, alkylcarbonyl, alkyloxycarbonyl and alkyloxyalkylcarbonyl.

5. (Previously Presented) A compound which is degraded *in vivo* to yield a compound according to claim 1.

6. (Canceled)

7. (Currently Amended) A method of treating a warm-blooded animal suffering from ~~The use of a compound according to claim 1 for the manufacture of a medicament for treating~~ depression, anxiety, movement disorders, psychosis, Parkinson's disease, ~~or and~~ body weight disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to said animal.

8. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

9. (Previously Presented) A process for making a pharmaceutical composition comprising mixing a compound according to claim 1 and a pharmaceutically acceptable carrier.

10. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 and one or more other compounds selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs.

11. (Canceled)

12. (Previously Presented) A method for the manufacture of a medicament for the treatment and/or prophylaxis of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders, said treatment comprising the simultaneous or sequential administration of a therapeutic amount of a compound according to claim 1 and a therapeutic amount of one or more other compounds

DOCKET NO.: JANS-0084 (JAB1747USPCT)

PATENT

Application No.: 10/524,123

Office Action Dated: May 17, 2007

selected from the group of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's drugs.

13. (Previously Presented) A process for making a pharmaceutical composition comprising mixing a compound according to claim 1 and a compound selected from the group of antidepressants, anxiolytics, antipsychotics and anti-Parkinson's disease drugs and a pharmaceutically acceptable carrier.